VTP50469 (VTP-50469) is a novel, oral and potent inhibitor of Menin-MLL protein protein interaction (Ki = 104 pM) with potential anticancer activity. Inhibition of the menin(MEN) and MLL1(KMT2A) interaction reverses leukemic gene expression driven by MLL-fusion proteins and is a potential targeted therapeutic strategy in MLL-rearranged AML.

纯度：≥98%

CAS：2169916-18-9